MHC II

Immutep Successfully Achieves Commercial Scale in Manufacturing of Eftilagimod Alpha

Retrieved on: 
Thursday, December 8, 2022

SYDNEY, AUSTRALIA, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the successful scale-up of the manufacturing of its lead product candidate eftilagimod alpha (“efti” or “IMP321”), a first-in-class soluble LAG-3 protein, with the completion of a 2,000L manufacturing run.

Key Points: 
  • In preparation for late-stage clinical trials and commercial production, Immutep has been working with WuXi Biologics to increase the efti manufacturing process from 200L to 2,000L capacity single-use bioreactors at the manufacturing plant in Wuxi city, China.
  • The first 2,000L manufacturing run has been performed successfully with all predefined release criteria met.
  • Marc Voigt, CEO of Immutep said: “Following compelling results from the TACTI-002 Phase II trial and promising initial clinical data from INSIGHT-003 recently presented at SITC 2022, we are pleased to announce this significant achievement reaching commercial scale in efti’s manufacturing by WuXi Biologics, an important long-term partner of Immutep.
  • Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease.

Immutep Enters into Second Clinical Trial Collaboration Agreement with Merck KGaA, Darmstadt, Germany, and Pfizer for New Combination Study of its First-in-Class LAG-3 Candidate, Eftilagimod Alpha, and Avelumab to Treat Urothelial Cancer

Retrieved on: 
Tuesday, November 29, 2022

The first patient is expected to be enrolled and dosed in H1 of calendar year 2023, after completing the necessary ethics and regulatory steps.

Key Points: 
  • The first patient is expected to be enrolled and dosed in H1 of calendar year 2023, after completing the necessary ethics and regulatory steps.
  • Urothelial cancer is a type of cancer in the bladder or urinary tract.
  • Under the Agreement, Immutep and Merck KGaA, Darmstadt, Germany will jointly fund the INSIGHT-005 study.
  • Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immuteps large pharmaceutical partners.

Immutep Granted New Patents in Japan and South Korea for First-in-Class LAG-3 Candidate, Eftilagimod Alpha in Chemo-Immunotherapy Combination

Retrieved on: 
Wednesday, November 9, 2022

SYDNEY, AUSTRALIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, is pleased to announce the grant of two new patents (numbers 7160345 and 10-2441425) entitled “Combined Preparations for the Treatment of Cancer” by the Japanese Patent Office and South Korean Patent Office, respectively.

Key Points: 
  • These new patents in Japan and South Korea were filed as divisional applications.
  • The patents protect Immuteps intellectual property relating to combination preparations comprising lead active immunotherapy candidate eftilagimod alpha (efti) and a chemotherapy agent which is oxaliplatin, carboplatin, or topotecan.
  • These new patents are notable because this family of patents protects a component of the triple combination therapy being evaluated in our INSIGHT-003 clinical trial.
  • We also have other families of patents and patent applications which add to the protective moat around this triple combination.

Immutep Announces Abstract Highlighting Eftilagimod Alpha Selected for SITC 2022 Annual Meeting Press Conference

Retrieved on: 
Friday, November 4, 2022

SYDNEY, AUSTRALIA, Nov. 04, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces its late-breaking abstract titled “Combining the antigen-presenting cell activator eftilagimod alpha (soluble LAG-3) and pembrolizumab: efficacy results from the 1st line non-small cell lung cancer cohort of TACTI-002 (Phase II)” has been selected by the Society for Immunotherapy of Cancer (SITC) Communications Committee to be presented at the SITC 2022 Annual Meeting Press Conference.

Key Points: 
  • It also upregulates the expression of key biological molecules like CXCL10 that further boost the immune systems ability to fight cancer.
  • Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease.
  • Additional LAG-3 product candidates, including antibodies for immune response modulation, are licensed to and being developed by Immuteps large pharmaceutical partners.
  • Further information can be found on the Companys website www.immutep.com or by contacting:

Immutep Late-Breaking Abstract Accepted for Oral Presentation on First-in-Class LAG-3 Therapeutic Eftilagimod Alpha at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

Retrieved on: 
Wednesday, November 2, 2022

SYDNEY, AUSTRALIA, Nov. 02, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces a late-breaking abstract relating to its phase II TACTI-002 trial has been accepted for an oral presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2022. The oral presentation will include new clinical data for eftilagimod alpha (“efti”), its first-in-class soluble LAG-3 protein, in combination with pembrolizumab in 1st line non-small cell lung cancer (NSCLC) patients. The 37th Annual SITC meeting will be held in Boston, MA and virtually from 8 to 12 November 2022.

Key Points: 
  • Abstracts for all three presentations will be available in a Journal for ImmunoTherapy of Cancer Supplement, which will be published on 7 November 2022 at 8 am EST.
  • The Abstracts will also be subsequently made available on the Investors section of Companys website under Presentations .
  • It also upregulates the expression of key biological molecules like CXCL10 that further boost the immune systems ability to fight cancer.
  • Immutep is a clinical stage biotechnology company leading the development of LAG-3 related immunotherapy products for the treatment of cancer and autoimmune disease.

Immutep Receives FDA Fast Track Designation for LAG-3 Therapeutic Eftilagimod Alpha for First Line Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, October 4, 2022

We are pleased to receive this Fast Track designation as it acknowledges eftis unique potential to empower the human immune system against cancer and significantly enhance patient responses to standard-of-care immunotherapy.

Key Points: 
  • We are pleased to receive this Fast Track designation as it acknowledges eftis unique potential to empower the human immune system against cancer and significantly enhance patient responses to standard-of-care immunotherapy.
  • Efti also offers a chemotherapy-free option for NSCLC patients in need of less toxic and more durable solutions, stated Marc Voigt, CEO of Immutep.
  • Efti is under evaluation for a variety of solid tumors including non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC) and HER2/HR+ metastatic breast cancer.
  • Efti has received Fast Track Designation in 1st line recurrent or metastatic HNSCC and in 1st line NSCLC from the United States Food and Drug Administration (FDA).

Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma

Retrieved on: 
Tuesday, September 6, 2022

The trial will evaluate Immuteps lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS).

Key Points: 
  • The trial will evaluate Immuteps lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting (prior to surgery) in up to 40 patients with select soft tissue sarcoma (STS).
  • Immutep will provide efti at no cost to the Maria Skodowska-Curie National Research Institute of Oncology and will technically support the trial.
  • The trial will be led by Principal Investigators, Dr. Katarzyna Kozak, M.D.
  • PhD., and Pawe Sobczuk, M.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skodowska-Curie National Research Institute of Oncology.

Immunomic Therapeutics Reports Preclinical Data on Its MCPγV-LT and Her2/Neu DNA Vaccines at the American Association for Cancer Research (AACR) Annual Meeting 2022

Retrieved on: 
Friday, April 8, 2022

The posters are accessible on the "Posters" section of Immunomic Therapeutics website at: https://www.immunomix.com/media/posters/ .

Key Points: 
  • The posters are accessible on the "Posters" section of Immunomic Therapeutics website at: https://www.immunomix.com/media/posters/ .
  • The majority of Merkel cell carcinomas (MCC), a rare and highly aggressive type of neuroendocrine skin cancer, are associated with Merkel cell polyomavirus (MCPyV) infection.
  • LTS220A, encoding a mutated form of MCPV-LT that diminishes its pro-oncogenic properties, was introduced into the UNITE platform.
  • We are highly encouraged by the data from the preclinical development for Her2-LAMP-sCD40L vaccine, stated Teri Heiland, PhD, Chief Scientific Officer of Immunomic Therapeutics.

Nanjing Leads Biolabs and BeiGene Announce Worldwide License and Collaboration Agreement for LBL-007 Anti-LAG-3 Antibody; BeiGene Granted Exclusive Commercialization Rights Outside of China

Retrieved on: 
Tuesday, December 14, 2021

BeiGene is the ideal partner for Leads Biolabs given its extensive experience in the development of oncology medicines worldwide and the compelling immuno-oncology combination opportunity in its pipeline.

Key Points: 
  • BeiGene is the ideal partner for Leads Biolabs given its extensive experience in the development of oncology medicines worldwide and the compelling immuno-oncology combination opportunity in its pipeline.
  • By collaborating with BeiGene, Leads Biolabs expects to significantly accelerate the development and commercialization of LBL-007.
  • BeiGene has also entered into a collaboration with Novartis granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.
  • Nanjing Leads Biolabs (Leads Biolabs) is a clinical-stage US-Sino joint venture company, focusing on development and commercialization of second-generation immuno-oncology therapeutics.